Semaglutide or Tirzepatide

Phase 3Peptide

NNational and Kapodistrian University of Athens

Semaglutide or Tirzepatide is one of 43 therapeutic programs targeting Obesity. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

ObesityEnrolling by invitation

ObesityPhase 3

Enrolling by invitation

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Amgen

Phase 3

7 2

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

1 3

Cagrisema

Novo Nordisk

Phase 3

5 4

Eloralintide

Eli Lilly

Phase 3

10 5

Belantamab Mafodotin-Blmf

Novo Nordisk

Phase 3

1 6

Elecoglipron

AstraZeneca

Phase 3

1 7

Semaglutide or Tirzepatide

NNational and Kapodistrian University of Athens

Phase 3

1 8

Avapro

Sanofi

Preclinical

1 9

Amidate

Calciferol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Recruiting

Obesity (disorder)

NCT07653412

Clinical

Trials by Indication[1]

Obesity1 trial

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Enrolling by invitation·MMayo Clinic·Approved·NCT07057310·30 enrolled

Obesity (Disorder)1 trial

Prediction of Response to GLP-1/GIP Receptor Agonists in Obesity Using Genetic Risk Score and SNP Profiling: A Prospective Cohort Study.

Recruiting·NNational and Kapodistrian University of Athens··NCT07653412·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Semaglutide or Tirzepatide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Semaglutide or Tirzepatide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National and Kapodistrian University of Athens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide
Highest Phase: Phase 3[1]
Company: NNational and Kapodistrian University of Athens

Semaglutide or Tirzepatide

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Obesity1 trial

Obesity (Disorder)1 trial

References

Drug Info

Quick Facts

Related News